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partial protein sequencing and degenerate-primer PCR
[9], and that once identified its sequence showed no re-
lationship to any other known prenyl transferase. Yet
dmaW homologs are evident in numerous secondary
metabolite clusters, including the newly identified terre-
quinone A cluster [1]. In the future, other previously un-
recognized, but essential and conserved, gene families
might be identified for other metabolite gene clusters.
For example, the loline alkaloid (LOL) gene cluster of
Neotyphodium uncinatum contains ten genes, none of
which fall into the four aforementioned categories [10].
Even so, the relationships of LOL proteins to pyridoxal
phosphate enzymes, monooxygenases, or nonheme-
iron oxygenases strongly suggest that this is a second-
ary metabolism cluster.
Thus, two approaches appear promising for identify-
ing novel secondary metabolism clusters in sequenced
genomes: identification of signature protein families
[2], and demonstration of coordinated regulation with
other metabolite gene clusters [1]. Bok et al. [1] demon-
strate that the latter approach holds considerable prom-
ise for Aspergillus species. The degree to which the
technique can be applied to other fungal groups de-
pends on whether global regulation is typical or atypical
across the kingdom. A promising observation is that ho-
mologs of laeA are apparent in sequenced genomes of
other fungi in the phylum Ascomycota. But, there is
actually an embarrassment of riches. For example, a
BLASTp search of LaeA sequence against the protein
database for Gibberella zeae PH-1—also known for its
secondary metabolites and toxins—brings up 37 hits
with E values ranging from 1 3 10247 to 7 3 10221 (per-
sonal observation). Obviously, these cannot all be global
regulators. Does the top of this list represent the func-
tional homolog of LaeA, or does the next one (at 9.7 3
10246), or do none of them? Follow-up studies of other
systems will have evolutionary implications as well. If
global regulation appears to be typical of diverse fungal
genera, what ecological conditions might they have in
common that would have selected this behavior? If, on
the other hand, other fungi tend not to exhibit global reg-
ulation of secondary metabolism, what are the ecologi-
cal variables that have led to such divergent regulatory
strategies?
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Makes a Finer Sift
Most partners of protein phosphatase 1 rely on an in-
stance of the so-called RVxF motif for interaction
with the enzyme. In this issue of Chemistry & Biology,
a stringent definition of the motif targeting high-
affinity instances enabled Meiselbach and colleagues
to recognize novel binding partners with high specific-
ity [1].
For a protein, a key to durable protection from mutation
is the acquisition of one or more essential functions that
involve interactions with multiple partners. Few proteinsare better placed to illustrate the success of this strategy
than protein phosphatase 1 (PP1), an enzyme that re-
moves phosphoryl moieties from Ser or Thr residues in
proteins [2–5]. Beginning in early eukaryotic evolution,
this enzyme formed interactions with proteins that target
and regulate its activity toward various specific sub-
strates. Some of the earliest of these alliances, presum-
ably including those with the mitotic regulator Sds22 [6]
and the less well characterized Inhibitor-3 [7], became in-
dispensable for eukaryotic survival. The ensuing need
for conservation of the different interaction sites in-
volved has severely constrained further mutation of the
enzyme [2].
However, the structural rigidity of PP1 has not halted
its functional evolution. To the contrary, to meet new
regulatory demands in different eukaryotic lineages, its
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7stable structure has continued to accommodate novel
interactions with inhibitors, substrate specifiers, which
restrict the access to the catalytic site, and targeting
proteins, which recruit PP1 to specific subcellular loca-
tions or substrates. For instance, some time before the
divergence of fungi and animals, PP1 and a coopted gly-
cogen-targeting protein engaged in the controlled de-
phosphorylation and reactivation of glycogen synthase
[2]. Bound to other regulatory subunits, PP1 functions
in the regulation of various aspects of cell cycle progres-
sion and arrest, the metabolism of small molecules and
macromolecules, actin and actomyosin reorganization,
and signaling through receptors, ion channels, and ion
pumps [3–5].
Nearly a decade ago, a peptide display study de-
scribed a short peptide motif that is sufficient for inter-
action with PP1 [8]. Interestingly, this motif, which con-
sists of a few basic residues followed by Val, a poorly
defined residue, and Phe or Trp, occurs in most PP1
binding proteins. At about the same time, the cocrystal-
lization of PP1 with a fragment of a glycogen-targeting
subunit revealed the binding of this very motif in atomic
detail; the Val and aromatic side chains nest in a hydro-
phobic channel at some distance from the catalytic site
of the enzyme, while the basic residues adhere to the
electrostatically favorable surface near the entrance of
the channel [9]. Although functional on their own, in-
stances of the RVxF motif, as it is most often referred
to, often join forces with additional PP1 binding sites.
The recently published crystal structure of a myosin-
targeting subunit in complex with PP1 nicely illustrates
this observation [10]. On the other hand, some well-
studied PP1 partners, like Sds22 [11], have been shown
to lack an RVxF sequence altogether, which leaves the
RVxF binding channel free to accommodate additional
protein ligands.
The prospect for the recognition of novel binding part-
ners of PP1 inspired approaches to a more rigorous de-
scription of the motif. Wakula et al. proposed a definition
based on known and experimentally validated RVxF in-
stances and an exhaustive exploration of the residues
allowed at the penultimate position of the motif [12].
The compatibility of a residue was derived from the in-
hibitory potency of mutated versions of a fragment of
the Nuclear Inhibitor of PP1 that depends on a functional
RVxF sequence for binding. The resulting formal defini-
tion of the motif read [KR]-X(0,1)-[VI]-{P}-[FW] (Val or Ile
separated by any residue but Pro from Phe or Trp,
with Arg or Lys at at least one of the two preceding po-
sitions). This definition recognizes virtually all estab-
lished RVxF instances, but with its predicted and ob-
served random occurrence of roughly one instance per
thousand residues (or per three average-length protein
sequences), it lacks specificity. Given a generous esti-
mate of about 200 genuine RVxF instances in the mam-
malian proteome [3], the specificity of the motif as de-
fined by Wakula et al [12] would approach 2.5%.
Hence, compatibility with this motif is an inadequate
screening criterion for candidate regulators of PP1,
even when combined with context filters that exclude
poorly conserved occurrences or instances in putative
extracellular and transmembrane regions.
In this issue, Meiselbach et al. suggest a more restric-
tive definition of the motif, based on the coprecipitationof PP1 with mutated versions of a PP1 binding fragment
of the mGluR7b receptor with an RVxF sequence [1]. A
complete loss of interaction in these pull-down assays
[1] roughly corresponded to a reduction of the inhibitory
potency by a factor of two in the inhibition assays [12].
The choice of a less sensitive binding assay resulted in
the exclusion of Ile from position 3 of their 5 residue mo-
tif and of about half of the naturally occurring residues
from positions 2 and 4. The sensitivity of the new defini-
tion appears somewhat disappointing, as it only re-
covers about 40% of the established RVxF instances.
However, at roughly one instance per ten thousand res-
idues, the predicted and the observed random occur-
rence of this stricter motif are an order of magnitude
lower than that of the earlier, more sensitive definition.
Under the assumption that the overall sensitivity ap-
proaches the 40% sensitivity among established in-
stances, this lower random occurrence should translate
to an improved specificity of about 10%. The authors
furthermore report that subsequent context filtering
can eliminate more than half of the candidate instances
based on a predicted segregation from the intracellular
PP1, which results in a combined expected specificity
of roughly 25%. Strikingly, on a small test set of proteins
not known to be binding partners, the proposed proce-
dure performed even better than expected. Pull-down
assays validated seven out of eight tested candidates,
and for each of those a competition assay demonstrated
the involvement of an RVxF sequence. Even when an al-
lowance is made for a substantial margin of error in view
of the small size of the test population, the efficiency of
the proposed screening procedure is very impressive.
Hence, a further exploration of the untested candidates
holds the promise of the identification of several dozens
of novel PP1 partners.
Notably, the huge gap between the expected and
observed specificity may indicate that the overall sensi-
tivity is considerably higher than the 40% coverage of
known RVxF instances. This hypothesis implies that
known binding partners bear more divergent RVxF in-
stances with a lower affinity for PP1. The distinction be-
tween primary and secondary partners of PP1 [2] may
offer an explanation. While the interaction of secondary
partners with PP1 is subordinate to a distinct principal
function, the recruitment, substrate specification, and
regulation of PP1 together constitute the core function
of primary PP1 partners. Primary partners, which in-
clude the majority of the known regulators, often rely
on multiple interaction sites for the various aspects of
their function. Cooperative binding of these sites may al-
leviate the affinity requirements for an involved RVxF in-
stance. The PP1-related function of secondary PP1
partners, on the other hand, is typically limited to the di-
rect recruitment of the phosphatase, which tends to be
involved in the regulation of the distinct core function
of that partner. An isolated PP1 binding site, typically
an easily evolvable RVxF sequence, may suffice for re-
cruitment if its affinity for the enzyme is high enough.
Most known examples of secondary PP1 partners are
receptors, ion channels, ion pumps, or scaffold proteins
[3]. Strikingly, five out of the seven candidates validated
by Meiselbach and coworkers and the mGluR7b para-
digm are also receptors and/or ion channels and there-
fore presumably secondary partners. If this subset
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ciently target secondary PP1 partners with high-affinity
RVxF instances. Interestingly, given that the number of
primary PP1 partners has stagnated in recent years,
secondary interactors show the highest potential for
growth via novel discovery approaches like the one pro-
posed by Meiselbach and coworkers. Other recently de-
scribed PP1 binding motifs [12–14] may inspire addi-
tional strategies.
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Specific Probes
for Chemokine Receptors
Chemokine receptors have attracted a good deal of
public attention as important therapeutic targets for
many diseases and disorders. In this issue of Chemis-
try & Biology, Kumar and colleagues propose a new
concept of synthetic modular modifications to gener-
ate unnatural chemokines, which exhibit high receptor
selectivity [1].
In a postgenome and proteome era, selective agonists
and antagonists can be highly useful for studies of re-
ceptor biology and for clinical applications. Chemokines
belong to a chemotactic cytokine family that attracts
and induces migration of leukocytes. Chemokines and
their receptors play fundamental roles in physiological
phenomena. Since these actions are relevant to many
pathological disorders such as cancer and AIDS, che-
mokine receptors are thought to be critical drug targets.
Chemokine receptors are members of the seven-
transmembraneGprotein-coupledreceptor (GPCR) fam-
ily, which transduce signals of corresponding chemo-
kines. The relationships between chemokines and their
receptors are highly interconnected and complicated:
a single chemokine recognizes a plurality of receptors,
while one chemokine receptor recognizes several che-
mokines. Numerous chemokines lack receptor selectiv-
ity. Unnatural chemokines that have high receptor selec-2. Ceulemans, H., Stalmans, W., and Bollen, M. (2002). Bioessays
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tivity would be practically useful, not only as specific
molecular probes for biological studies, but also as
drug leads for clinical application. Furthermore, the de-
velopment of systematic strategies to synthesize such
unnatural ligands would be desirable.
In this issue of Chemistry & Biology, Kumar and col-
leagues report unnatural synthetic molecules as chemi-
cal probes of chemokine receptors. They present the
concept of modular modifications to generate unnatural
chemokines that possess receptor selectivity [1]. They
created synthetically and modularly modified (SMM)-
chemokines based on a combination of total chemical
synthesis and modular modification. They chose
CXCR4 [2] and CCR5 [3–7] as target receptors with the
aim of potentially developing anti-AIDS drugs, since
these are the two principal coreceptors that are required
for HIV-1 entry. In addition to HIV infection/AIDS, CXCR4
has also been shown to be involved in several problem-
atic diseases, such as cancer metastasis [8, 9], leukemia
[10, 11], and rheumatoid arthritis [12, 13]. As such,
CXCR4 represents one of the greatest therapeutic tar-
gets for the above diseases. Although natural chemo-
kines for CXCR4 and CCR5 can inhibit HIV infection by
blocking gp120 binding regions on CXCR4 and CCR5,
respectively, serious problems remain concerning se-
lectivity, side effects, and toxicity profiles. vMIP-II,
which recognizes various chemokine receptors, was
chosen among chemokine ligands as the parent mole-
cule for modification [14]. For a detailed discussion of
CXCR4/CCR5 antagonists, readers are referred to re-
cent reviews [15, 16].
